New clinical data shows that combining targeted oncology drugs vopimetostat and daraxonrasib produces durable responses in pancreatic cancer patients without the use of traditional chemotherapy. Meanwhile, safety reports for the next-generation obesity therapy retatrutide have identified potential cardiovascular complications, including arrhythmias, in a small percentage of trial participants. These developments underscore the industry's dual focus on developing chemotherapy-free combination treatments and monitoring the long-term tolerability of metabolic drugs.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
Views312
Ali NematiBlogUI.author_articles
